Chemo Pharma Laboratories Ltd Stock Price Today (NSE: CHEMOPH)
Fundamental Score
Chemo Pharma Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Chemo Pharma Laboratories Ltd share price today is ₹109.00, up +0.00% on NSE/BSE as of 18 June 2026. Chemo Pharma Laboratories Ltd (CHEMOPH) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹15.02 (Cr). The 52-week high for CHEMOPH share price is ₹150.75 and the 52-week low is ₹95.00. The company has a Return on Equity (ROE) of 3.47% and a debt-to-equity ratio of 0.01.
Chemo Pharma Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Chemo Pharma Laboratories Ltd share price chart: 8.84% return over the past month. 52-week high ₹150.75, 52-week low ₹95.00.
Chemo Pharma Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹117.20 | ₹117.20 | ₹107.00 | ₹109.00 | 1.10K (Cr) | |
| ₹105.55 | ₹118.00 | ₹105.55 | ₹106.55 | 382.00 (Cr) | |
| ₹120.00 | ₹120.00 | ₹105.00 | ₹112.30 | 5.06K (Cr) | |
| ₹115.00 | ₹118.75 | ₹114.00 | ₹117.50 | 901.00 (Cr) | |
| ₹102.00 | ₹108.95 | ₹102.00 | ₹105.25 | 578.00 (Cr) | |
| ₹107.10 | ₹116.00 | ₹107.10 | ₹107.95 | 575.00 (Cr) | |
| ₹137.00 | ₹137.00 | ₹114.00 | ₹116.85 | 358.00 (Cr) | |
| ₹143.70 | ₹143.70 | ₹117.00 | ₹123.60 | 2.00K (Cr) | |
| ₹112.80 | ₹135.35 | ₹106.00 | ₹128.80 | 2.44K (Cr) | |
| ₹103.60 | ₹113.50 | ₹103.55 | ₹112.80 | 116.00 (Cr) |
Chemo Pharma Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹105.05 | ₹143.70 | ₹95.00 | ₹109.00 | +3.76% | |
| ₹131.50 | ₹138.00 | ₹95.00 | ₹107.25 | -18.44% | |
| ₹115.00 | ₹141.80 | ₹112.00 | ₹130.85 | +13.78% | |
| ₹118.75 | ₹132.95 | ₹112.00 | ₹114.35 | -3.71% | |
| ₹125.00 | ₹150.75 | ₹109.05 | ₹118.75 | -5.00% | |
| ₹114.70 | ₹149.00 | ₹112.45 | ₹125.30 | +9.24% | |
| ₹120.55 | ₹121.80 | ₹113.20 | ₹117.00 | -2.94% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Micro-cap shell with no operations attempting a highly speculative turnaround; avoid.
WHAT'S HAPPENING NOW (last 2-4 weeks)
No major catalysts found after live search. The India Pharma 2026 event is currently underway (April 13-14) in New Delhi, focusing on innovation and India's role in global pharma. The event aims to promote India's pharmaceutical capabilities and encourage collaboration.
CORE STORY (THE REAL GAME)
CHEMOPH is a micro-cap shell company attempting a turnaround by acquiring a business in power and chemicals. The market is likely speculating on the success of this diversification strategy.
- India Pharma 2026 event underway, but no specific impact on CHEMOPH
- Micro-cap momentum can drive short-term price swings
- Speculation on potential acquisition in power/chemicals
- Successful acquisition announcement
- Positive news flow from India Pharma 2026 related to government support for the sector
- Significant increase in trading volume
- Micro/SME cap = high liquidity risk
- No current operations
- Turnaround is highly speculative
- Opacity around acquisition target
- Negative Free Cash Flow of ₹-0.98 Cr
No significant FII/DII activity. Promoter holding stable at 27.89%.
Indian pharmaceutical industry is transitioning towards value-led innovation, but CHEMOPH is not participating in this trend.
No. Free Cash Flow 5Y: ₹-0.98 Cr
Expect continued volatility driven by speculation. The company's future depends entirely on the success of the acquisition, which is uncertain.
Primary Thesis Risk
Turnaround fails, stock collapses to zero.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Chemo Pharma Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Chemo Pharma Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CHEMOPH across key market metrics for learning purposes.
Positive Indicators
2 factors identified
Conservative Debt Levels (D/E: 0.01)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
9 factors identified
Below-Average Return on Equity (3.47%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (5.17%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Profit Decline Concern (-83.61%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (1.39% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (1.39% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-0.98 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Low Promoter Commitment (27.89%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
Limited Institutional Interest (FII+DII: 0.17%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Chemo Pharma Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Chemo Pharma Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Chemo Pharma Laboratories LtdChemo Pharma La...Selected✓ CHEMOPH • 506365 | 1.3/100 | ₹109.00₹109 | ₹15.02₹15.02 | — — | 3.47%Poor 3.47% Poor | 5.17%Poor 5.17% Poor | 0.01Excellent 0.0 Excellent | 1.39%Average 1.39% Average | — — | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 65.2/100 | ₹1844.30₹1844 | ₹433738.68₹433738.68 | 37.57Average 37.6 Average | 16.86%Good 16.86% Good | 20.21%Excellent 20.21% Excellent | 0.07Excellent 0.1 Excellent | 23.78%Excellent 23.78% Excellent | 9.87%Good 9.87% Good | 0.89% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 67.9/100 | ₹6797.50₹6798 | ₹170445.88₹170445.88 | 68.59Average 68.6 Average | 15.35%Good 15.35% Good | 20.44%Excellent 20.44% Excellent | 0.01Excellent 0.0 Excellent | 10.41%Good 10.41% Good | 11.65%Good 11.65% Good | 0.47% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 65.3/100 | ₹4537.80₹4538 | ₹126430.62₹126430.62 | 58.36Average 58.4 Average | 26.52%Excellent 26.52% Excellent | 27.05%Excellent 27.05% Excellent | 0.33Excellent 0.3 Excellent | 13.84%Good 13.84% Good | 7.72%Good 7.72% Good | 0.86% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 59/100 | ₹1418.20₹1418 | ₹123059.76₹123059.76 | 22.62Average 22.6 Average | 17.77%Good 17.77% Good | 22.72%Excellent 22.72% Excellent | 0.01Excellent 0.0 Excellent | 28.68%Excellent 28.68% Excellent | 9.97%Good 9.97% Good | 0.85% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 59.2/100 | ₹1319.00₹1319 | ₹105224.96₹105224.96 | 18.23Average 18.2 Average | 17.96%Good 17.96% Good | 22.69%Excellent 22.69% Excellent | 0.16Excellent 0.2 Excellent | 22.28%Excellent 22.28% Excellent | 13.26%Good 13.26% Good | 0.63% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 66.7/100 | ₹2276.40₹2276 | ₹95148.15₹95148.15 | 22.00Average 22.0 Average | 20.62%Excellent 20.62% Excellent | 21.30%Excellent 21.30% Excellent | 0.32Excellent 0.3 Excellent | 54.88%Excellent 54.88% Excellent | 8.11%Good 8.11% Good | 0.58% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 68.7/100 | ₹956.95₹957 | ₹94253.78₹94253.78 | 18.74Average 18.7 Average | 21.21%Excellent 21.21% Excellent | 24.31%Excellent 24.31% Excellent | 0.38Excellent 0.4 Excellent | 25.92%Excellent 25.92% Excellent | 10.27%Good 10.27% Good | 1.17% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 50.6/100 | ₹2420.40₹2420 | ₹92012.53₹92012.53 | 52.62Average 52.6 Average | 14.68%Average 14.68% Average | 15.98%Good 15.98% Good | 0.55Good 0.6 Good | 11.73%Good 11.73% Good | 15.79%Excellent 15.79% Excellent | 0.04% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 28.8/100 | ₹1435.90₹1436 | ₹70798.69₹70798.69 | 20.69Average 20.7 Average | 11.08%Average 11.08% Average | 14.18%Average 14.18% Average | 0.22Excellent 0.2 Excellent | 3.87%Average 3.87% Average | 6.55%Good 6.55% Good | 0.33% |
Alkem Laboratories LtdAlkem Laborator... ALKEM • 539523 | 59.5/100 | ₹5451.50₹5452 | ₹67075.29₹67075.29 | 28.54Average 28.5 Average | 19.39%Good 19.39% Good | 20.38%Excellent 20.38% Excellent | 0.18Excellent 0.2 Excellent | 13.93%Good 13.93% Good | 9.21%Good 9.21% Good | 0.80% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price433738.68 Cr
- Divis Laboratories Ltd share price170445.88 Cr
- Torrent Pharmaceuticals Ltd share price126430.62 Cr
- Cipla Ltd share price123059.76 Cr
- Dr Reddys Laboratories Ltd share price105224.96 Cr
Chemo Pharma Laboratories Ltd Quarterly Performance
Latest quarterly metrics for CHEMOPH — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-83.61%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
N/A
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
1.39%
Compounded annual net profit growth over 5 years
Chemo Pharma Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for CHEMOPH — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Chemo Pharma Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Chemo Pharma Laboratories Ltd (CHEMOPH) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Chemo Pharma Laboratories Ltd
About CHEMOPH (Chemo Pharma Laboratories Ltd)
Chemo Pharma Laboratories Ltd is a historical pharmaceutical entity rooted in the Indian subcontinent, specifically Mumbai. Established in 1942, the company boasts a rich legacy in... the research, development, and manufacture of pharmaceutical and bulk drug products. For decades, Chemo Pharma Laboratories Ltd played a significant role in the healthcare sector, contributing to the production of vital medications and active pharmaceutical ingredients. Their legacy is intertwined with the evolution of the pharmaceutical industry in India, having navigated changing regulatory landscapes and technological advancements during their active years. The company's historical operations involved a range of activities, from research and development to large-scale production and distribution, supporting healthcare needs across a broad spectrum. The company's journey took an interesting turn in October 2025, marking a significant shift in its identity and strategic direction. At this time, Chemo Pharma Laboratories Ltd underwent a transformation, changing its name to Starsource Multitrade Limited. This change signaled a departure from its established focus on pharmaceuticals and a move towards new ventures and opportunities. While the precise details of this transition remain subject to public information, the renaming marked a pivotal moment in the company's history, indicating a strategic realignment of its business model and objectives. The former identity as Chemo Pharma Laboratories Ltd remains a testament to its pharmaceutical past, forever etched in the annals of the Indian pharmaceutical industry. As Starsource Multitrade Limited, the company experienced a period where its operational activities became limited. While the company had a legacy in the pharmaceutical sector, Starsource Multitrade Limited did not have significant operations and was transitioning away from the active production of pharmaceutical and bulk drug products. The change was a reflection of the evolving business climate, and the company's efforts to change and adapt to new opportunities. The journey from Chemo Pharma Laboratories Ltd to Starsource Multitrade Limited encapsulates the dynamic nature of the business world, where companies must constantly reassess their strategies and navigate shifting market forces to remain relevant and competitive.
Company Details
Key Leadership
CHEMOPH Share Price: Frequently Asked Questions
What is the current share price of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd (CHEMOPH) trades at ₹109.00 on NSE and BSE. Market cap ₹15.02 (Cr). Educational data only.
What is the P/E ratio of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has a P/E of N/Ax vs industry average 31.77x.
What is the Bull Run score for Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has a Bull Run score of 1.3/100 based on 25+ financial parameters.
Does Chemo Pharma Laboratories Ltd pay dividends?
Chemo Pharma Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has ROE of 3.47%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Chemo Pharma Laboratories Ltd?
Chemo Pharma Laboratories Ltd has debt-to-equity of 0.01.
Is Chemo Pharma Laboratories Ltd a good investment?
Bull Run gives Chemo Pharma Laboratories Ltd a score of 1.3/100. This is not investment advice — consult a SEBI-registered advisor.